EP1002 - ECE_3406 - Real-world BMI outcomes in adult patients with acquired hypothalamic obesity treated with setmelanotide for up to 9 months in France
Acquired hypothalamic obesity (aHO) arises from physical injury to the hypothalamus caused by trauma, tumours, treatment-related damage, inflammation, or developmental abnormalities, leading to disrupted melanocortin-4 receptor (MC4R) signalling and marked by accelerated, sustained weight gain. In a 52-week place...